Intellia Therapeutics Inc (NASDAQ:NTLA) shares, rose in value on Thursday, March 06, with the stock price up by 5.71% to the previous day’s close as strong demand from buyers drove the stock to $9.90.
Actively observing the price movement in the last trading, the stock closed the session at $9.36. Referring to stock’s 52-week performance, its high was $32.00, and the low was $8.30. On the whole, NTLA has fluctuated by 2.91% over the past month.
With the market capitalization of Intellia Therapeutics Inc currently standing at about $1.02 billion, investors are eagerly awaiting this quarter’s results, scheduled for in April.
Wall Street analysts also predicted that the company’s y-o-y revenues would reach 11.33M.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that NTLA’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of NTLA currently trading nearly -5.07% and -7.77% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 44.78, while the 7-day volatility ratio is showing 10.79% which for the 30-day chart, stands at 8.62%. Furthermore, Intellia Therapeutics Inc (NTLA)’s beta value is 2.15, and its average true range (ATR) is 0.92.
A comparison of Intellia Therapeutics Inc (NTLA) with its peers suggests the former has fared considerably weaker in the market. NTLA showed an intraday change of 5.71% in last session, and over the past year, it shrunk by -69.44%%.
Data on historical trading for Intellia Therapeutics Inc (NASDAQ:NTLA) indicates that the trading volumes over the past 3 months, they’ve averaged 3.06 million. According to company’s latest data on outstanding shares, there are 102.03 million shares outstanding.
Nearly 5.55% of Intellia Therapeutics Inc’s shares belong to company insiders and institutional investors own 90.19% of the company’s shares. The stock has fallen by -15.09% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the NTLA stock heading into the next quarter.
